Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2422

1.

An observational study of how clinicians use cardiovascular risk assessment to inform statin prescribing decisions.

Robinson T, Jackson R, Wells S, Kerr A, Marshall R.

N Z Med J. 2017 Oct 6;130(1463):28-38.

PMID:
28981492
2.

Effects of Statin Intensity and Adherence on the Long-Term Prognosis After Acute Ischemic Stroke.

Kim J, Lee HS, Nam CM, Heo JH.

Stroke. 2017 Oct;48(10):2723-2730. doi: 10.1161/STROKEAHA.117.018140. Epub 2017 Sep 15.

PMID:
28916672
3.

Optimizing Cholesterol Treatment in Patients With Muscle Complaints.

Rosenson RS, Baker S, Banach M, Borow KM, Braun LT, Bruckert E, Brunham LR, Catapano AL, Elam MB, Mancini GBJ, Moriarty PM, Morris PB, Muntner P, Ray KK, Stroes ES, Taylor BA, Taylor VH, Watts GF, Thompson PD.

J Am Coll Cardiol. 2017 Sep 5;70(10):1290-1301. doi: 10.1016/j.jacc.2017.07.752. Review.

PMID:
28859793
4.

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.

HPS3/TIMI55–REVEAL Collaborative Group, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ.

N Engl J Med. 2017 Sep 28;377(13):1217-1227. doi: 10.1056/NEJMoa1706444. Epub 2017 Aug 28.

PMID:
28847206
5.

Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.

Ference BA, Kastelein JJP, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, Packard CJ, Laufs U, Brook RD, Oliver-Williams C, Butterworth AS, Danesh J, Smith GD, Catapano AL, Sabatine MS.

JAMA. 2017 Sep 12;318(10):947-956. doi: 10.1001/jama.2017.11467.

PMID:
28846118
6.

Balancing Primary Prevention and Statin-Induced Diabetes Mellitus Prevention.

Rochlani Y, Kattoor AJ, Pothineni NV, Palagiri RDR, Romeo F, Mehta JL.

Am J Cardiol. 2017 Oct 1;120(7):1122-1128. doi: 10.1016/j.amjcard.2017.06.054. Epub 2017 Jul 14. Review.

PMID:
28797470
7.

Meta-analysis of Placebo-Controlled Randomized Controlled Trials on the Prevalence of Statin Intolerance.

Riaz H, Khan AR, Khan MS, Rehman KA, Alansari SAR, Gheyath B, Raza S, Barakat A, Luni FK, Ahmed H, Krasuski RA.

Am J Cardiol. 2017 Sep 1;120(5):774-781. doi: 10.1016/j.amjcard.2017.05.046. Epub 2017 Jun 13. Review.

PMID:
28779871
8.

Guideline-Based Statin Eligibility, Cancer Events, and Noncardiovascular Mortality in the Framingham Heart Study.

Pursnani A, Massaro JM, D'Agostino RB Sr, O'Donnell CJ, Hoffmann U.

J Clin Oncol. 2017 Sep 1;35(25):2927-2933. doi: 10.1200/JCO.2016.71.3594. Epub 2017 Jul 12.

PMID:
28700275
9.

Cardiovascular Risk Stratification and Statin Eligibility Based on the Brazilian vs. North American Guidelines on Blood Cholesterol Management.

Cesena FHY, Laurinavicius AG, Valente VA, Conceição RD, Santos RD, Bittencourt MS.

Arq Bras Cardiol. 2017 Jun;108(6):508-517. doi: 10.5935/abc.20170088. English, Portuguese.

10.

Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke.

Heller DJ, Coxson PG, Penko J, Pletcher MJ, Goldman L, Odden MC, Kazi DS, Bibbins-Domingo K.

Circulation. 2017 Sep 19;136(12):1087-1098. doi: 10.1161/CIRCULATIONAHA.117.027067. Epub 2017 Jul 7.

PMID:
28687710
11.

Utility of 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines in HIV-Infected Adults With Carotid Atherosclerosis.

Phan BAP, Weigel B, Ma Y, Scherzer R, Li D, Hur S, Kalapus SC, Deeks S, Hsue P.

Circ Cardiovasc Imaging. 2017 Jul;10(7). pii: e005995. doi: 10.1161/CIRCIMAGING.116.005995.

12.

Hypercholesterolaemia and vascular dementia.

Appleton JP, Scutt P, Sprigg N, Bath PM.

Clin Sci (Lond). 2017 Jun 30;131(14):1561-1578. doi: 10.1042/CS20160382. Print 2017 Jul 15. Review.

PMID:
28667059
13.

Statins for Primary Prevention of Cardiovascular Disease: Review of Evidence and Recommendations for Clinical Practice.

Kazi DS, Penko JM, Bibbins-Domingo K.

Med Clin North Am. 2017 Jul;101(4):689-699. doi: 10.1016/j.mcna.2017.03.001. Review.

PMID:
28577620
14.

Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial.

Han BH, Sutin D, Williamson JD, Davis BR, Piller LB, Pervin H, Pressel SL, Blaum CS; ALLHAT Collaborative Research Group.

JAMA Intern Med. 2017 Jul 1;177(7):955-965. doi: 10.1001/jamainternmed.2017.1442.

15.

The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.

Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Giouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tselepis AD, Tsioufis K, Tziomalos K, Tzotzas T, Vasiliadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C.

Metabolism. 2017 Jun;71:17-32. doi: 10.1016/j.metabol.2017.02.014. Epub 2017 Mar 4. Review.

PMID:
28521870
16.

Prevalence of Elevated Cardiovascular Risks in Young Adults: A Cross-sectional Analysis of National Health and Nutrition Examination Surveys.

Patel KK, Taksler GB, Hu B, Rothberg MB.

Ann Intern Med. 2017 Jun 20;166(12):876-882. doi: 10.7326/M16-2052. Epub 2017 May 16.

PMID:
28505660
17.

USPSTF recommendations: A 2017 roundup.

Campos-Outcalt D.

J Fam Pract. 2017 May;66(5):310-314.

PMID:
28459891
18.

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics.

Landray MJ, Reveal Collaborative Group; L. Bowman, F. Chen, E. Sammons, J.C. Hopewell, K. Wallendszus, W. Stevens, E. Valdes-Marquez, S. Wiviott, C.P. Cannon, E. Braunwald, R. Collins, M.J. Landray (Writing Committtee).

Am Heart J. 2017 May;187:182-190. doi: 10.1016/j.ahj.2017.02.021. Epub 2017 Feb 21.

19.

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.

Schmidt AF, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP.

Cochrane Database Syst Rev. 2017 Apr 28;4:CD011748. doi: 10.1002/14651858.CD011748.pub2. Review.

PMID:
28453187
20.

Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).

Khera AV, Demler OV, Adelman SJ, Collins HL, Glynn RJ, Ridker PM, Rader DJ, Mora S.

Circulation. 2017 Jun 20;135(25):2494-2504. doi: 10.1161/CIRCULATIONAHA.116.025678. Epub 2017 Apr 27.

PMID:
28450350

Supplemental Content

Loading ...
Support Center